ACAD
ACADIA Pharmaceuticals Inc
22.20$
-12.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.1% | -10.9% | +17.6% | +3.5% | +3.7% | -5.9% | +8.3% | +5.3% | +1.9% | -5.6% | +14.9% | – | |
| – | +22.4% | +28.3% | -20.6% | +3.4% | +15.6% | -6.5% | +1.7% | +4.4% | +21.1% | -5.5% | +14.2% | – | |
| – | +8.2% | -14.2% | +22.3% | +3.5% | +2.7% | -5.8% | +8.9% | +5.4% | +0.3% | -5.6% | +15.0% | – | |
| – | -57.5% | -10.6% | +27.7% | -12.6% | +51.2% | -22.3% | -0.4% | +12.7% | -3.5% | -9.3% | +6.1% | – | |
| – | +4.3% | +5.8% | +8.4% | +13.9% | -2.4% | -2.9% | +5.6% | -0.1% | +16.7% | +9.9% | -6.3% | – | |
| – | -30.1% | -5.9% | +15.3% | +3.4% | -57.8% | +142.8% | +3.3% | +4.6% | +8.7% | +3.1% | -2.5% | – | |
| – | – | -56.5% | +100.1% | +4.0% | +385.1% | -87.4% | +67.8% | +10.4% | -51.4% | -126.5% | – | – | |
| – | – | -47.1% | +77.0% | +4.4% | +315.1% | -82.8% | +44.8% | +10.9% | -41.0% | -84.9% | +1,067.4% | – | |
| – | -146.8% | – | -14.7% | +59.3% | +187.1% | -49.3% | +54.1% | -300.7% | – | – | +4,252.6% | – | |
| – | – | -63.9% | +101.7% | -1.9% | +338.7% | -86.8% | +40.4% | +169.2% | +281.1% | -98.7% | +766.1% | – | |
| – | – | -35.8% | +49.8% | +4.1% | -70.5% | +151.8% | +40.4% | +10.2% | -38.5% | -76.2% | +364.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.